We are live on ! Find out more
KCM

KRS Capital Management Portfolio holdings

AUM $215M
1-Year Est. Return 69.3%
This Fund
S&P 500
This Quarter Est. Return
-5.88%
1 Year Est. Return
+69.3%
3 Year Est. Return
+232.71%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$72.5M
AUM Growth
+$2.3M
Cap. Flow
+$515K
Cap. Flow %
0.71%
Top 10 Hldgs %
42.25%
Holding
101
New
4
Increased
56
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$346K
2
LLY icon
Eli Lilly
LLY
+$273K
3
WDAY icon
Workday
WDAY
+$223K
4
COST icon
Costco
COST
+$205K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$198K

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$365K
2
UNP icon
Union Pacific
UNP
+$246K
3
COHR icon
Coherent
COHR
+$235K
4
FDX icon
FedEx
FDX
+$232K
5
ENB icon
Enbridge
ENB
+$214K

Sector Composition

Rank Sector Weight
1 Technology 43.31%
2 Healthcare 15.22%
3 Consumer Discretionary 9.06%
4 Financials 6.72%
5 Communication Services 5.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNP icon
101
Union Pacific
UNP
$175B
– –
-1,156
Closed -$246K
1 2 3 4
5

Similar funds

VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
VEA
Virtus ETF Advisers New York $215M AUM 53.68% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
TSS
Taylor Securities Services Harrisburg, Pennsylvania $214M AUM
CMBA
C.M. Bidwell & Associates Honolulu, Hawaii $214M AUM 18.82% 1-Year Est. Return
IH
IES Holdings Houston, Texas $214M AUM

KRS Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, KRS Capital Management held 101 positions worth $72.5M, up 3.3% from $70.2M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

KRS Capital Management's Q3 2022 filing shows 4 new, 56 increased, 16 reduced and 6 closed positions. Its largest new stake was Pfizer: 7,115 shares worth $311K. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $365K.

By sector, the portfolio is most concentrated in Technology at 43% of assets, down from 48% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • KRS Capital Management's largest Q3 2022 buy was Pfizer: 7,115 shares worth $311K.
  • KRS Capital Management added most to Eli Lilly in Q3 2022, an estimated $273K increase.
  • KRS Capital Management's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $365K.
  • KRS Capital Management fully exited Union Pacific in Q3 2022, selling an estimated $246K.
  • KRS Capital Management's ten largest holdings make up 42% of its $72.5M portfolio in Q3 2022.
  • KRS Capital Management opened 4 new positions and closed 6 in Q3 2022.
  • KRS Capital Management's portfolio value rose 3.3% quarter-over-quarter to $72.5M.

Based on KRS Capital Management's 13F filing for Q3 2022, filed 21 Oct 2022.